15533-68-3

Usage

Uses

Used in Pharmaceutical Industry:
2,4(1H,3H)-Pyrimidinedione, dihydro-1-phenylis used as a key intermediate in the synthesis of various drugs and pharmaceutical products. Its unique chemical structure allows for the development of new therapeutic agents with potential applications in treating a wide range of diseases.
Used in Cardiovascular Disease Treatment:
2,4(1H,3H)-Pyrimidinedione, dihydro-1-phenylis used as a therapeutic agent for the treatment of cardiovascular diseases. Its antihypertensive and hypolipidemic properties make it a promising candidate for managing high blood pressure and reducing cholesterol levels, thereby improving overall cardiovascular health.
Used in Material Science and Chemical Processes:
Due to its unique chemical structure and properties, 2,4(1H,3H)-Pyrimidinedione, dihydro-1-phenylmay have potential applications in the development of new materials and chemical processes. Its versatility and reactivity can be harnessed to create innovative products and improve existing processes in various industries.

Upstream product

• 71868-35-4 PCM-0102883 
• 90841-26-2 N-(3-bromo-propionyl)-N'-phenyl-urea 
• 64-10-8 phenyl carbamate 
• 814-68-6 acryloyl chloride 
• 21321-07-3 1-phenyluracil 
• 591-50-4 iodobenzene 
• 62-53-3 aniline 

Downstream Products

• 101012-60-6 5-bromo-1-phenyl-dihydro-pyrimidine-2,4-dione 
• 53369-66-7 5-bromo-1-phenyl pyrimidine-2, 4 (1H, 3H)-dione 
• 667908-87-4 C₁₃H₁₄N₂O₄ 

Relevant academic research and scientific papers

CRBN LIGANDS AND USES THEREOF

The present invention provides compounds, compositions thereof, and methods of using the same for the inhibition of CRBN, and the treatment of CRBN-mediated disorders.

DIHYDROURACIL COMPOUNDS AS ANTI-ICTOGENIC OR ANTI-EPILEPTOGENIC AGENTS

Methods and compounds useful for the inhibition of convulsive disorders, including epilepsy, are disclosed. The methods and compounds of the invention inhibit or prevent or treat ictogenesis, epileptogenesis, or epileptogenesis-associated conditions. Methods for preparing the compounds of the invention are also described. Particularly preferred compounds of the invention include Formula 1 as described herein.

Photochemistry of Uracils in Halogenated Solvents

The photochemistry of uracil and 1-substituted and 1,3-disubstituted uracils in CHBr3-CH2Cl2 is investigated.Photolysis of uracil leads to the formation of 5,6-dibromo-5,6-dihydrouracil as the main product, with 5-bromouracil as the by-product.In contrast with this the 5-bromouracils are formed as the main products by the photolysis of 1-substituted and 1,3-disubstituted uracils, with the corresponding 5,6-dihydro- and 5-bromo-5,6-dihydrouracils as the by-products.The kinetics of the bromination reaction have also been investigated and based on these results a free radical mechanism is proposed.